Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study was designed to determine the efficacy and safety of neoadjuvant docetaxel and
epirubicin (DE) with or without human recombinant endostatin (endostar) for breast cancer
patients. The hypothesis of this protocol is that a combined angiogenesis inhibiting therapy
to chemotherapy could further benefit breast cancer patients.